Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
9 studies found for:    acc-001
Show Display Options
RSS Create an RSS feed from your search for:
acc-001
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Completed Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001 (vanutide cridificar)
2 Terminated
Has Results
A Long Term Extension Study Evaluating ACC-001 With QS-21 in Subjects With Mild to Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001+ QS21 (3mcg);   Biological: ACC-001 (10 mcg) + QS-21;   Biological: ACC-001+QS-21 (30mcg)
3 Completed Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Drug: ACC-001+ QS21;   Drug: ACC-001;   Drug: ACC-001 + QS21
4 Completed
Has Results
Study Evaluating ACC-001 in Japanese Patients With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001;   Other: QS-21;   Other: PBS
5 Completed
Has Results
Study Evaluating ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001 + QS-21;   Biological: QS-21;   Other: Diluent: Phosphate Buffered Saline;   Biological: ACC-001
6 Completed
Has Results
Amyloid Imaging And Safety Study Of ACC-001 In Subjects With Early Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: ACC-001 3 μg/ QS-21 50 μg;   Biological: ACC-001 10 μg/ QS-21 50 μg;   Other: Placebo- Phosphate buffered saline (PBS)
7 Terminated
Has Results
Long Term Extension Study Evaluating Safety, Tolerability And Immunogenicity Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Intervention: Biological: ACC-001
8 Completed
Has Results
Study Evaluating Safety, Tolerability, And Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer Disease
Interventions: Biological: ACC-001 + QS-21;   Biological: ACC-001;   Biological: QS-21;   Drug: Placebo: Phosphate buffered saline
9 Completed
Has Results
Safety, Tolerability, And Immunogenicity Study Of ACC-001 In Japanese Subjects With Mild To Moderate Alzheimer's Disease
Condition: Alzheimer's Disease
Interventions: Biological: ACC-001;   Other: QS-21

Indicates status has not been verified in more than two years